BeiGene, Ltd.
ONC
$230.98
$2.841.25%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.90B | 3.35B | 3.05B | 2.72B | 2.41B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.90B | 3.35B | 3.05B | 2.72B | 2.41B |
| Cost of Revenue | 607.64M | 546.54M | 458.27M | 416.12M | 372.98M |
| Gross Profit | 3.29B | 2.80B | 2.59B | 2.30B | 2.04B |
| SG&A Expenses | 1.87B | 1.75B | 1.63B | 1.58B | 1.48B |
| Depreciation & Amortization | -- | -- | -377.80K | -189.80K | -2.80K |
| Other Operating Expenses | 24.60K | 25.15M | 500.90K | 500.90K | 500.90K |
| Total Operating Expenses | 4.48B | 4.24B | 3.92B | 3.79B | 3.60B |
| Operating Income | -586.12M | -892.55M | -864.61M | -1.08B | -1.19B |
| Income Before Tax | -549.20M | -804.06M | -454.95M | -716.49M | -810.01M |
| Income Tax Expenses | 112.97M | 53.22M | 51.86M | 51.05M | 54.81M |
| Earnings from Continuing Operations | -662.17 | -857.27 | -506.81 | -767.54 | -864.82 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -662.17M | -857.27M | -506.81M | -767.54M | -864.82M |
| EBIT | -586.12M | -892.55M | -864.61M | -1.08B | -1.19B |
| EBITDA | -473.22M | -798.72M | -773.36M | -987.18M | -1.10B |
| EPS Basic | -82.04 | -106.77 | -63.43 | -95.83 | -108.00 |
| Normalized Basic EPS | -3.22 | -6.96 | -4.86 | -6.43 | -7.00 |
| EPS Diluted | -82.04 | -106.77 | -63.43 | -95.83 | -108.00 |
| Normalized Diluted EPS | -3.22 | -6.96 | -4.86 | -6.43 | -7.00 |
| Average Basic Shares Outstanding | 420.20M | 418.02M | 418.26M | 418.20M | 418.09M |
| Average Diluted Shares Outstanding | 32.32M | 32.15M | 32.17M | 32.17M | 32.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -2.19% | -1.69% | -3.07% | -2.03% | -1.80% |